Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record.

Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study

Evans, T.R. Jeffry, Yellowlees, Ann, Foster, Elizabeth, Earl, Helena, Cameron, David A., Hutcheon, Andrew W., Coleman, Robert E., Perren, Timothy, Gallagher, Christopher J., Quigley, Mary, Crown, John, Jones, Alison L., Highley, Martin, Leonard, Robert C.F., Mansi, Janine L. · 2005 · Journal of Clinical Oncology

Abstract

Purpose: To compare the clinical and pathologic response rates of doxorubicin and cyclophosphamide (AC) with doxorubicin and docetaxel (AD) as primary chemotherapy in women with primary or locally advanced breast cancer. Patients and Methods: Eligible patients with histologically proven breast cancer with primary tumors ≥ 3 cm, inflammatory or locally advanced disease, and no evidence of metastases were randomly assigned to receive a maximum of six cycles of either doxorubicin (60 mg/m 2) plus cyclophosphamide (600 mg/m 2) administered intravenously (IV) every 3 weeks or doxorubicin (60 mg/m 2) plus docetaxel (75 mg/m 2) IV every 3 weeks, followed by surgery on completion of chemotherapy. Results: A total of 363 patients were randomly assigned to AC (n = 180) or AD (n = 183). A complete clinical response was observed in 17% and 20% of patients treated with AC and AD, respectively (P = .42). Overall (complete and partial) clinical response rates for AC and AD were 61% and 70%, respectively (P = .06). There was no significant difference in either the pathologic complete response rates in the breast with AC (24%) and AD (21%; P = .61) or in the number of patients with positive axillary nodes at surgery with AC (61%) and AD (66%; P = .28). At a median follow-up of 32 months, there is no significant difference between the two groups for the number of relapses. Conclusion: In contrast to the positive results reported for sequential docetaxel after AC as primary chemotherapy of breast cancer, our data do not suggest a benefit for simultaneous AD over AC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.156

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 175

Metadata

Authors
Evans, T. R. J., Yellowlees, A., Foster, E., Earl, H., Cameron, D. A., Hutcheon, A. W., Coleman, R. E., Perren, T., Gallagher, C. J., Quigley, M., Crown, J., Jones, A. L., Highley, M., Leonard, R. C. F., & Mansi, J. L.
Venue
Journal of Clinical Oncology
Published
2005-05-01
Volume
23
Issue
13
Pages
2988-2995
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2128822091
Cited by
175
References
0
FWCI
5.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study. https://app.cochat.ai/papers/10.1200/jco.2005.06.156
The paper
Evans, T. R. J., Yellowlees, A., Foster, E., Earl, H., Cameron, D. A., Hutcheon, A. W., Coleman, R. E., Perren, T., Gallagher, C. J., Quigley, M., Crown, J., Jones, A. L., Highley, M., Leonard, R. C. F., & Mansi, J. L. (2005). Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.06.156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.